Basic Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 872-886
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.872
Figure 5
Figure 5 Xihuang pills treatment inhibits tumour growth in vivo. SMMC7721 cells were injected subcutaneously into the lower right side of 5-week-old BALB/c male nude mice. After a model of subcutaneous xenograft tumours was successfully established in nude mice, animals were randomly divided into two groups. Each group was then treated with either 0.2 mL of distilled water (control) or 78 mg/kg of body weight Xihuang pills. A: Representative images of subcutaneous xenograft tumours at the end of treatment; B: Subcutaneous tumour weights measured at the end of the treatment; C: Average subcutaneous tumour volume measured every 2 d; D: Average mouse body weight measured every 2 d. The experiment was repeated three times, and the data are presented as the means ± SD. The results were analysed using one-way analysis of variance, followed by the least significant difference test. aP < 0.05 and bP < 0.01 compared with the control group. XHP: Xihuang pills.

  • Citation: Teng YJ, Deng Z, Ouyang ZG, Zhou Q, Mei S, Fan XX, Wu YR, Long HP, Fang LY, Yin DL, Zhang BY, Guo YM, Zhu WH, Huang Z, Zheng P, Ning DM, Tian XF. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway. World J Gastrointest Oncol 2022; 14(4): 872-886
  • URL: https://www.wjgnet.com/1948-5204/full/v14/i4/872.htm
  • DOI: https://dx.doi.org/10.4251/wjgo.v14.i4.872